

UNITED STATI DEPARTMENT OF COMMERCE United States Fat int and Trademark Offic

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 01/28/00 MCGROGAN M L01-06CIP 09/494,088 **EXAMINER** HM22/0509 BAKER, A Barbara J Luther Chartered **ART UNIT** PAPER NUMBER 18124 Wedge Parkway #516 Reno NV 89511 1632 DATE MAILED: 05/09/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

DEST AVAILABLE COM

		Application No.	Applicant(s)
Office Action Summary		09/494,088	MCGROGAN ET AL.
		Examiner	Art Unit
		Anne M. Baker	1632
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply			
THE I - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REF MAILING DATE OF THIS COMMUNICATION nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory perion to reply within the set or extended period for reply will, by stately received by the Office later than three months after the may be patent term adjustment. See 37 CFR 1.704(b).	N. 1.136 (a). In no event, however, may a eply within the statutory minimum of third od will apply and will expire SIX (6) MON tute, cause the application to become AE	reply be timely filed by (30) days will be considered timely. ITHS from the mailing date of this communication. SANDONED (35 U.S.C. § 133).
1)	Responsive to communication(s) filed on _	·	
2a) <u></u> □	This action is FINAL . 2b)	This action is non-final.	
3)□	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims			
4)⊠	Claim(s) 1-22 is/are pending in the applicat	ion.	
4a) Of the above claim(s) is/are withdrawn from consideration.			
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7)	Claim(s) is/are objected to.		
8)⊠	Claims <u>1-22</u> are subject to restriction and/o	or election requirement.	
Application Papers			
9) The specification is objected to by the Examiner.			
10) The drawing(s) filed on is/are objected to by the Examiner.			
11)⊠ The proposed drawing correction filed on <u>28 January 2000</u> is: a) approved b) disapproved.			
12) The oath or declaration is objected to by the Examiner.			
Priority under 35 U.S.C. § 119			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).			
a) All b) Some * c) None of:			
	1. Certified copies of the priority docume	ents have been received.	
	2. Certified copies of the priority docume	ents have been received in A	Application No
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).			
* See the attached detailed Office action for a list of the certified copies not received.			
14)⊠ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).			
Attachment(s)			
_	tice of References Cited (PTO-892)	18) 🔲 Interview	w Summary (PTO-413) Paper No(s)
16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 20) Other:			

Application/Control Number: 09/494,088

Art Unit: 1632

DETAILED ACTION

Page 2

Claims 1-22 are pending in the instant application.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-17 and 19-22, drawn to a method of producing dopaminergic neuronal cells, a

dopaminergic neuronal cell, a method of improving the survival of human neuronal cells for

transplantation, a pharmaceutical composition, a method of preparing human neuronal cells

suitable for treating Parkinson's Disease, classified in class 435, subclass 368.

II. Claim 18, drawn to a chimeric non-human mammal, classified in class 800, subclass 8.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are patentably distinct, one from the other because the inventions are drawn to

distinct methods and compositions. The chimeric mammal of the invention of Group II is not required to

practice the method of the invention of Group I. Although the cell compositions of the invention of Group I

can be used to produce the chimeric mammal of the invention of Group II, the cells can be used in other

methods, such as in in vitro assays to determine the effect of various compounds on the growth and survival

of the cells of the invention. Thus, the methods of the inventions of Groups I and II are patentably distinct,

each from the other.

Because these inventions are distinct for the reasons given above and have acquired a separate status

in the art as shown by their different classification and recognized divergent subject matter and because the

)

Application/Control Number: 09/494,088 Page 3

Art Unit: 1632

searches required for the separate inventions are not coextensive, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne-Marie Baker whose telephone number is (703) 306-9155. The examiner can normally be reached Monday through Thursday and alternate Fridays from 9:30 AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Karen Hauda, can be reached on (703) 305-6608. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-8724.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the patent analyst, Kay Pinkney, whose telephone number is (703) 305-3553.

Anne-Marie Baker, Ph.D.

ANNE-MARIE BARRER

anne-marie Faker